Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
114 participants
OBSERVATIONAL
2016-08-31
2019-06-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neuronal Responses to Social Feedback in Major Depressive Disorder
NCT02180607
Stress Sensitivity and Reward Responsivity in Depression
NCT02798094
Model-based Defining of Subtypes of Depression and Optimal Treatment: an Integrated Techniques Module.
NCT04518592
Behavioral Processes Underlying Reward Processing in Depression
NCT00205933
Study of the Neural Circuits Underlying the Negative Emotional Bias of Depressive Disorders and Their Response to Ketamine
NCT06630065
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It has been known for over 30 years in nonhuman animals that the endogenous opioid system, particularly the ยต-opioid receptor (MOR) system, regulates social distress and social reward behaviors. Using positron emission tomography, we recently showed that social rejection and acceptance produced robust MOR-mediated neurotransmission in specific brain areas, which correlated with changes in mood and behavior. This study was the first to show that the endogenous opioid system responds to social cues in humans. The proposed project will examine the MOR system in the clinically important trait of RS. Since the neurotransmitter mechanisms of RS are unknown, we seek to first understand the basic neurobiology of RS in a healthy population, prior to studying clinical populations.
The overall hypothesis is that RS is associated with MOR function. Those with higher RS compared to lower RS are hypothesized to have overall lower MOR activation during social rejection and acceptance, leading to greater distress and dampened pro-social behavior. Numerous animal studies have also established that the MOR system is strongly influenced by harmful social environments. Therefore, we will also examine the role of childhood maltreatment (CM), a negative early life experience known to be one of the highest risk factors for developing depression and anxiety. The goal of this project is to determine how RS and CM interact to determine patterns of MOR binding during baseline, social rejection, and social acceptance in a healthy population. We will also examine how RS, mediated through MOR activation, influences mood and behavior.
The impact of this research is to provide the first major step towards understanding a neurotransmitter mechanism for RS, with the long-term goal of predicting and treating its associated disorders.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy Controls
Healthy men and women ages 18-25 years
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Right-handed
* Native English speaker
* Not currently in a romantic relationship
* Willing and able to participate in a PET scan
Exclusion Criteria
* Not pregnant
* Consume less than 5 cigarettes per week and less than 14 alcoholic drinks per week, on average
* No use of recreational or street drugs in the past two years (e.g. marijuana)
* Willing to abstain from alcohol and/or tobacco for 48 hours
* No major untreated medical problems
* Never diagnosed with a psychiatric or neurological disorder
* Potential problems with having an MRI scan (claustrophobia, metal objects, etc.)
18 Years
25 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Michigan
OTHER
National Institute of Mental Health (NIMH)
NIH
Stony Brook University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
David Hsu
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David T Hsu, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Stony Brook University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Michigan
Ann Arbor, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.